A subgroup analysis of the CATNON trial with 154 IDHwt astrocytoma with molecular features of glioblastoma showed that MGMT promotor methylation was prognostic for overall survival but not predictive for temozolomide chemotherapy in this cohort [7]. This evidence concerns the gene MGMT and astrocytoma (excluding glioblastoma).